199 Bay St, Suite 4000, Commerce Court West, Toronto, ON
Year called to bar: 1994 (ON)
Michael has more than 25 years of experience in banking and financial services law, with a particular specialization in corporate and commercial finance. His practice is focused on the areas of banking, syndicated lending, leveraged finance, project finance, and mergers & acquisitions. Michael regularly advises Canadian and foreign financial institutions and borrowers with respect to the structuring and negotiation of syndicated loan transactions, acquisition financings, take-over bid financings, leveraged buyouts, corporate reorganizations, workouts, and mergers & acquisitions. Michael is recognized as a leading lawyer in all major directories and publications.
As part of the transaction, an affiliate of OMERS subscribed for an aggregate of $30 million of Dye & Durham common shares, on a private placement basis
Digital Colony, the global digital infrastructure investment platform of Colony Capital, Inc., and a leading investor, owner and operator of companies enabling the next generation of mobile and Internet connectivity, acquired Beanfield Technologies Inc. (Beanfield)
Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, completed the recapitalization of approximately US$4 billion of secured and unsecured debt in September 2018 pursuant to a plan of arrangement (the “CBCA Plan”) under the Canada Business Corporations Act (“CBCA”).
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.
